A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs MEDI-6570 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors MedImmune
- 10 Dec 2019 Planned End Date changed from 20 Jul 2020 to 28 Jul 2020.
- 10 Dec 2019 Planned primary completion date changed from 20 Jul 2020 to 28 Jul 2020.
- 10 Dec 2019 Status changed from recruiting to active, no longer recruiting.